10 Clinical Trials To Look Out For In 2025

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

Clinical Trial
An EMA paper discusses specific characteristics of single-arm trials (Shutterstock)

In 2025, the first Phase III clinical readout for a PROTAC degrader is expected in an important milestone for the targeted protein degradation (TPD) field.

The VERITAC-2 study is comparing the orally-bioavailable, small-molecule estrogen receptor PROTAC protein degrader vepdegestrant, which targets the estrogen receptor, against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from Scrip Perspectives